The role of autoantibodies as diagnostic markers of autoimmune hepatitis

Expert Review of Clinical Immunology

Volumn 2, Issue 1, 2006, Pages 33-48

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN ANTIBODY; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; HISTONE ANTIBODY; LIVER ANTIGEN; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ACUTE HEPATITIS; ALLOGRAFT; AUTOIMMUNE HEPATITIS; CHROMATIN; CHRONIC HEPATITIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; HUMAN; IMMUNOASSAY; LIVER CYTOSOL; LIVER TRANSPLANTATION; NONHUMAN; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; STANDARDIZATION; WORKSHOP;

EID: 33748501065     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.1.33     Document Type: Review

References (101)

1. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31, 929-938 (1999).
2. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem. 40, 127-164 (2005).
3. Doherty DG, Penzotti JE, Koelle DM et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J. Immunol. 161, 3527-3535 (1998).
4. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36, 479-497 (2002).
5. Cassani F, Cataleta M, Valentini P et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26, 561-566 (1997).
6. Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 48, 2173-2181 (2003).
7. Adams LA, Lindor ED, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 99, 1316-1320 (2004).
8. Bianchi FB, Muratori P, Muratori L. New autoantibodies and autoantigens in autoimmune hepatitis. Clin. Liver Dis. 6, 785-797 (2002).
9. Muratori P, Muratori L, Cassani F et al. Antimultiple nuclear dots (anti-MND) and antiSp100 antibodies in hepatic and rheumatological diseases. Clin. Exp. Immunol. 127, 172-175 (2002).
10. Muratori P, Muratori L, Ferrari R et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am. J. Gastroenterol. 98, 431-437 (2003).
11. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 24, 322-329 (2004).
12. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107, 200-207 (1994).
13. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in Type 1 autoimmune hepatitis. Dig. Dis. Sci. 42, 1688-1696 (1997).
14. Czaja AJ. Behavior and significance of autoantibodies in Type 1 autoimmune hepatitis. J. Hepatol. 30, 394-401 (1999).
15. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol. 37, 315-329 (2003).
16. Vergani D, Alvarez F, Bianchi FB et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Hepatitis Group. J. Hepatol. 41, 677-683 (2004).
17. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 120, 239-249 (2001).
18. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in Type 1 autoimmune hepatitis. Hepatology 24, 1068-1073 (1996).
19. Chretien-Leprince P, Ballot E, Andre C et al. Diagnostic value of antiF-actin antibodies in a French multicenter study. Ann. NY Acad. Sci. 1050, 266-273 (2005).
20. Andersen P, Small JV, Andersen HK, Sobieszek A. Reactivity of smooth-muscle antibodies with F- and G-actin. Immunology 37, 705-709 (1979).
21. Fusconi M, Cassani F, Zauli D et al. Anti-actin antibodies: a new test for an old problem. J. Immunol. Methods 130, 1-8 (1990).
22. Cancado ELR, Vilas-Boas LS, Abrantes-Lemos CP et al. Heat serum inactivation as a mandatory procedure for anti-actin antibody detection in cell culture. Hepatology 23, 1098-1104 (1996).
23. Cancado ELR, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J. Immunol. 17, 223-228 (2001).
24. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P450 monooxygenase. J. Clin. Invest. 88, 1370-1378 (1991).
25. Kerkar N, Choudhuri K, Ma Y et al. Cytochrome P4502D6193-212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody Type 1-positive liver disease. J. Immunol. 170, 1481-1489 (2003).
26. Gueguen M, Boniface O, Bernard O, Clerc F, Cartwright T, Alvarez F. Identification of the main epitope on human cytochrome P450 IID6 recognized by antiliver kidney microsome antibody. J. Immunol. 4, 607-615 (1991).
27. Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by antiliver-kidney microsome type-1 antibodies (LKM1). Eur. J. Immunol. 23, 1105-1111 (1993).
28. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of the antiliver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 104, 1762-1767 (1993).
29. Homberg J-C, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody Type 1: a second type of 'autoimmune hepatitis. Hepatology 7, 1333-1339 (1987).
30. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome Type 1 in adults with chronic active hepatitis. Gastroenterology 103, 1290-1295 (1992).
31. Kerremans ALM. Cytochrome P450 isoenzymes - importance for the internist. Neth. J. Med. 48, 237-243 (1996).
32. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology 42, 675-682 (2005).
33. Gregorio GV, Choudhuri K, Ma Y et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin. Exp. Immunol. 133, 404-413 (2003).
34. Bogdanos DP, Lenzi M, Okamoto M et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients associated with the possession of HLA B51. Int. J. Immunopathol. Pharmacol. 17, 83-92 (2004).
35. Reddy RK, Krawitt EL, Homberg JC et al. Absence of antiLKM1 in hepatitis C viral infection in the United States. J. Viral. Hepat. 2, 175-179 (1995).
36. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoinumme hepatitis Type 2. Gastroenterology 106, 1603-1610 (1994).
37. Gerotto M, Pontisso P, Giostra F et al. Analysis of the hepatitis C virus genome in patients with antiLKM-1 autoantibodies. J. Hepatol. 21, 273-276 (1994).
38. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am. J. Gastroenterol. 92, 2197-2200 (1997).
39. Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Laudanna AA, Kalil J. Different HLA profiles confer susceptibility to autoimmune hepatitis Type 1 and 2. Am. J. Gastroenterol. 93, 1394-1395 (1998).
40. Muratori P, Czaja AJ, Muratori L et al. Evidence of a genetic basis for the different geographical occurrences of liver/kidney microsomal antibody Type 1 in hepatitis C. World J. Gastroenterol. (In Press) (2005).
41. Manns M, Zanger U, Gerken G et al. Patients with Type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 12, 127-132 (1990).
42. Lohr H, Manns M, Kyriatsoulis A et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin. Exp. Immunol. 84, 297-302 (1991).
43. Baeres M, Herkel J, Czaja AJ et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51, 259-264 (2002).
44. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105, 1522-1528 (1993).
45. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1, 292-294 (1987).
46. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18, 1-9 (1993).
47. Kanzler S, Weidemann C, Gerken G et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J. Hepatol. 31, 635-640 (1999).
48. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/ liver pancreas and HLA risk factors in Type 1 autoinumme hepatitis. Am. J. Gastroenterol. 97, 413-419 (2002).
49. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13, 701-706 (1991).
50. Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and Type 1 autoimmune hepatitis. Hepatology 25, 317-323. (1997)
51. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev. 174, 250-259 (2000).
52. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig. Dis. Sci. 47, 2139-2150 (2002).
53. Wies I, Brunner S, Henninger J, Herkel J, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355, 1510-1515 (2000).
54. Costa M, Rodriques-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNA(Ser)Sec complex recognized by autoantibodies from patients with Type 1 autoimmune hepatitis. Clin. Exp. Immunol. 121, 364-374 (2000).
55. Volkmann M, Martin L, Baurle A et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically reacts with sera from patients with autoimmune hepatitis. Hepatology 33, 591-596 (2001).
56. Torres-Collado AX, Czaja AJ, Gelpi C. AntitRNA(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int. 25, 410-419 (2005).
57. Ballot E, Bruneel A, Labas V, Johanet C. Identification of rat targets of antisoluble liver antigen autoantibodies by serologic proteome analysis. Clin. Chem. 49, 634-643 (2003).
58. Bogdanos DP, Bianchi I, Ma Y, Mitry RR, Mieli-Vergani G, Vergani D. Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin. Chem. 50, 682-683 (2004).
59. Ma Y, Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 35, 658-664 (2002).
60. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschefelde K-H. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 11, 606-612 (1990).
61. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimune chronic active hepatitis. Lancet 2, 954-956 (1984).
62. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in Type 1 autoimmune hepatitis. Dig. Dis. Sci. 41, 1733-1740 (1996).
63. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29, 10009-10022 (1990).
64. Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin. Liver Dis. 11, 215-222 (1991).
65. Hajoui O, Martin S, Alvarez F. Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin. Exp. Immunol. 113, 339-345 (1998).
66. Schreiter T, Liu C, Gerken G, Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprortein receptor using recombinant receptor subunit H1. J. Immunol. Methods 301, 1-10 (2005).
67. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 37, 195-201 (2004).
68. Abuaf N, Johanet C, Chretien P et al. Characterization of the liver cytosol antigen Type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 16, 892-898 (1992).
69. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody Type 1 and liver cytosol antibody Type 1 concentrations in Type 2 autoimmune hepatitis. Gut 42, 721-726 (1998).
70. Bridoux-Henno L, Maggiore G, Johanet C et al. Features and outcome of autoimmune hepatitis Type 2 presenting with isolated positivity for antiliver cytosol antibody. Clin. Gastroenterol. Hepatol. 2, 825-830 (2004).
71. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Antiliver cytosolic antigen Type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 21, 58-62 (1995).
72. Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 116, 643-649 (1999).
73. Muratori L, Sztul E, Muratori P et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody Type 1. Hepatology 34, 494-501 (2001).
74. Lapierre P, Johanet C, Alvarez F. Characterization of the B cell response of patients with antiliver cytosol autoantibodies in Type 2 autoimmune hepatitis. Eur. J. Immunol. 33, 1869-1878 (2003).
75. Renous R, Lapierre P, Djilali-Shah I, Vitozzi S, Alvarez F. Characterization of the antigenicity of the formiminotransferase-cyclodeaminase in Type 2 autoimmune hepatitis. Exp. Cell Res. 292, 332-341 (2004).
76. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis Type 1. J. Gastroenterol. Hepatol. 15, 1176-1182 (2000).
77. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig. Dis. Sci. 48, 1658-1664 (2003).
78. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in Type 1 autoimmune hepatitis. Gastroenterology 108, 1159-1166 (1995).
79. Zauli D, Ghetti S, Grassi A et al. Antineutrophil cytoplasmic antibodies in Type 1 and Type 2 autoimmune hepatitis. Hepatology 25, 1105-1107 (1997).
80. Terjung B, Herzog V, Worman HJ et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 28, 332-340 (1998).
81. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive Type 1-autoimmune hepatitis. Hepatology 26, 567-572 (1997).
82. Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J. Hepatol. 23, 32-38 (1995).
83. Chen M, Shirai M, Czaja AJ et al. Characterization of antihistone antibodies in patients with Type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 13, 483-489 (1998).
84. Czaja AJ. Treatment of autoimmune hepatitis. Semin. Liver Dis. 22, 365-377 (2002).
85. Czaja AJ. Current concepts in autoimmune hepatitis. Ann. Hepatol. 4, 6-24 (2005).
86. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol. 40, 644-650 (2004).
87. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in Type 1 autoimmune hepatitis. Gastroenterology 110, 848-857 (1996).
88. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol. Dietol. 51, 313-333 (2005).
89. González-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 4, 302-310 (2001).
90. Kerkar N, Hadzic N, Davies ET et al. De novo autoimmune hepatitis after liver transplantation. Lancet 353, 409-413 (1998).
91. Heneghan MA, Portmann BC, Norris SM et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 34, 464-470 (2001).
92. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 8, 505-513 (2002).
93. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104, 1755-1761 (1993).
94. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin. Gastroenterol. Hepatol. 2, 107-112 (2004).
95. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 352, 26-29 (1998).
96. Czaja AJ. The variant forms of autoimmune hepatitis. Ann. Intern. Med. 125, 588-598 (1996).
97. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28, 360-365 (1998).
98. Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1, 63-70 (1999).
99. Vento S, DiPerri G, Garofano T et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2, 926 (1989).
100. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am. J. Gastroenterol. 90, 1206-1211 (1995).
101. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of Type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 39, 1066-1074 (2004).